Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
May 06, 2020 16:05 ET
|
Esperion Therapeutics, Inc.
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets Commercially Available in...
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
April 30, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May...
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
April 20, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– Esperion to Receive $60 Million Upfront Payment – – Up to $510 Million in Total Milestones – – Substantial Tiered Royalties – – Combines Esperion’s Expertise in Lipid Management with...
Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference
April 09, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
April 06, 2020 07:05 ET
|
Esperion Therapeutics, Inc.
– First Non-Statin, LDL-C Lowering Combination Medicine Ever Approved in Europe – – NUSTENDI Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other...
Esperion Announces European Commission Approval of the NILEMDO™ (bempedoic acid) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
April 06, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients – – NILEMDO Is Approved for Patients Who Require Additional...
Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare
March 30, 2020 16:15 ET
|
Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option –– Esperion Aims to Set New Industry Standard by...
Esperion to Host Analyst and Investor Day Event on May 30
May 07, 2019 05:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m....
Esperion to Present at the Needham & Company 18th Annual Healthcare Conference
April 02, 2019 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 02, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, cost-effective, convenient,...
Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results
April 01, 2019 16:15 ET
|
Esperion Therapeutics, Inc.
– Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant –– Over 24-Weeks, Bempedoic Acid Was Observed to be Safe,...